170 related articles for article (PubMed ID: 18592360)
21. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells.
Hashimoto D; Asakura S; Miyake S; Yamamura T; Van Kaer L; Liu C; Tanimoto M; Teshima T
J Immunol; 2005 Jan; 174(1):551-6. PubMed ID: 15611282
[TBL] [Abstract][Full Text] [Related]
22. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.
Kataoka Y; Iwasaki T; Kuroiwa T; Seto Y; Iwata N; Hashimoto N; Ogata A; Hamano T; Kakishita E
Immunology; 2001 Jul; 103(3):310-8. PubMed ID: 11454060
[TBL] [Abstract][Full Text] [Related]
23. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
24. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
[TBL] [Abstract][Full Text] [Related]
25. Involvement of both donor cytotoxic T lymphocytes and host NK1.1+ T cells in the thymic atrophy of mice suffering from acute graft-versus-host disease.
Onoe Y; Harada M; Tamada K; Abe K; Li T; Tada H; Nomoto K
Immunology; 1998 Oct; 95(2):248-56. PubMed ID: 9824483
[TBL] [Abstract][Full Text] [Related]
26. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
[TBL] [Abstract][Full Text] [Related]
27. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.
Yi T; Zhao D; Lin CL; Zhang C; Chen Y; Todorov I; LeBon T; Kandeel F; Forman S; Zeng D
Blood; 2008 Sep; 112(5):2101-10. PubMed ID: 18596226
[TBL] [Abstract][Full Text] [Related]
28. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
29. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.
Mariotti J; Foley J; Ryan K; Buxhoeveden N; Kapoor V; Amarnath S; Fowler DH
Blood; 2008 Dec; 112(12):4765-75. PubMed ID: 18625883
[TBL] [Abstract][Full Text] [Related]
30. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
31. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
33. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4.
Kim JH; Choi EY; Chung DH
J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047
[TBL] [Abstract][Full Text] [Related]
34. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease.
Zhang Y; Hexner E; Frank D; Emerson SG
J Immunol; 2007 Sep; 179(5):3305-14. PubMed ID: 17709547
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
[TBL] [Abstract][Full Text] [Related]
36. Regulatory T cells and IL-17-producing cells in graft-versus-host disease.
Teshima T; Maeda Y; Ozaki K
Immunotherapy; 2011 Jul; 3(7):833-52. PubMed ID: 21751953
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin-resistant effector T-cell therapy.
Fowler DH
Immunol Rev; 2014 Jan; 257(1):210-25. PubMed ID: 24329799
[TBL] [Abstract][Full Text] [Related]
39. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
[TBL] [Abstract][Full Text] [Related]
40. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease.
Tawara I; Maeda Y; Sun Y; Lowler KP; Liu C; Toubai T; McKenzie AN; Reddy P
Exp Hematol; 2008 Aug; 36(8):988-96. PubMed ID: 18410989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
